Analyst Price Targets — ABBV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 10:54 am | — | Piper Sandler | $303.00 | $265.97 | TheFly | AbbVie price target raised to $303 from $298 at Piper Sandler |
| August 17, 2026 10:50 am | — | Wells Fargo | $300.00 | $249.45 | TheFly | AbbVie price target raised to $300 from $295 at Wells Fargo |
| August 13, 2026 9:40 am | Alexandria Hammond | Wolfe Research | $300.00 | $248.66 | TheFly | AbbVie upgraded to Outperform from Peer Perform at Wolfe Research |
| August 4, 2026 10:46 am | — | Guggenheim | $288.00 | $245.08 | TheFly | AbbVie price target raised to $288 from $261 at Guggenheim |
| August 3, 2026 12:01 pm | — | Morgan Stanley | $296.00 | $246.26 | TheFly | AbbVie price target raised to $296 from $278 at Morgan Stanley |
| August 3, 2026 10:41 am | Gary Nachman | Canaccord Genuity | $290.00 | $250.88 | StreetInsider | Abbvie (ABBV) PT Raised to $290 at Canaccord |
| July 29, 2026 9:06 am | — | Barclays | $300.00 | $263.48 | TheFly | AbbVie price target raised to $300 from $275 at Barclays |
| July 22, 2026 10:39 am | — | Canaccord Genuity | $282.00 | $256.15 | TheFly | AbbVie price target raised to $282 from $273 at Canaccord |
| July 13, 2026 4:29 pm | — | UBS | $260.00 | $247.05 | TheFly | AbbVie price target raised to $260 from $230 at UBS |
| July 13, 2026 12:20 pm | — | BMO Capital | $300.00 | $246.69 | TheFly | AbbVie price target raised to $300 from $258 at BMO Capital |
Latest News for ABBV
AbbVie (ABBV), the pharmaceutical and biotechnology giant, put its cancer pipeline squarely on investors' radar Thursday, with shares priced at $260.445. Etenta
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
AbbVie said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus investigator's choice of standard available therapies Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a…
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.